SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
or Other Jurisdiction
|(Commission File Number)||(IRS
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|(Title of each class)||(Trading Symbol)||(Name of exchange on which registered)|
|The Stock Market LLC|
|The Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On March 16, 2022, Jasper Therapeutics, Inc. (the “Company”) made available a corporate presentation (the “Presentation”). Representatives of the Company intend to use the Presentation in industry conferences, investor conferences and investor meetings from time to time.
The information in this Item 7.01, including the Presentation attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
|99.1||Jasper Therapeutics, Inc. Investor Presentation|
|104||Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|JASPER THERAPEUTICS, INC.|
|Date: March 16, 2022||By:||/s/ Jeet Mahal|
|Chief Financial Officer, Chief Business Officer and Corporate Secretary|
Transforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022
2 JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements . All statements other than statements of historical fact contained in this Presentation, including statements regarding the future opportunities and prospects of Jasper Therapeutics, Inc . (together with its subsidiary, “Jasper” or the “Company”), including milestones, business strategy, and plans and objectives for future operations, are forward - looking statements . Jasper has based these forward - looking statements on its estimates and assumptions and its current expectations and projections about future events . These forward - looking statements are subject to a number of risks, uncertainties and assumptions, including those contained in the “Risk Factors” section of the Company’s Registration Statement on Form S - 4 declared effective by the U . S . Securities and Exchange Commission (the “SEC”) on August 26 , 2021 , and any Annual Reports on Form 10 - K, Quarterly Reports on Form 10 - Q and Current Reports on Form 8 - K that the Company has filed or may subsequently file with the SEC . In light of these risks, uncertainties and assumptions, the forward - looking events and circumstances discussed in this Presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward - looking statements . Accordingly, you should not rely upon forward - looking statements as predictions of future events . Jasper undertakes no obligation to update publicly or revise any forward - looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Jasper’s expectations . Industry and Market Data Certain data in this Presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources . Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation . Such data involves risks and uncertainties and is subject to change based on various factors . Trademarks The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use shou ld not be construed as an endorsement of the products or services of the Company.
3 JSP191 is an investigative drug and is not approved for any indication • Science targeting the central role of stem cells to cure a growing number of fatal diseases • JSP191: First in class Phase 1/2 anti - CD117 antibody conditioning agent • Clinical data in SCID & AML/ MDS transplant populations, Potential Q1 2023 AML/ MDS pivotal FPI • New therapeutic approach for disease modification in lower risk MDS patients to initiate in 2022 • Jasper mRNA stem cells: Novel hematopoietic stem cell mRNA platform to expand the curative potential of allogeneic and autologous cellular therapy • In vivo POC in 2022, potential IND in 2023 • Team with expertise in hematopoietic stem cell transplant and track record in drug development • Validating corporate and academic partnerships • Cash runway through AML / MDS pivotal study start Jasper Highlights
4 JSP191 is an investigative drug and is not approved for any indication JSP191 stem cell conditioning for AML/ MDS and SCID transplant patients JSP191 blocks CD117 (Stem Cell Factor Receptor) leading to hematopoietic stem and progenitor cell depletion • Synergistic with other stem cell targeting mechanisms (radiation 1 , 5 - azacytidine 2 ) JSP191 designed to minimize off target / safety effects • Designed to remove effector cell recruitment and mast cell activation • CD117 also expressed on mast cells, germ cells, Cajal (GI) cells, melanocytes Two ongoing clinical trials with near term initiation of AML / MDS pivotal study  Xue X, et al Blood. 2010; 116(24):5419 - 5422.  Bankova AK, Pang WW, Velasco BJ, Long - Boyle JR, Shizuru JA. Blood Adv . 2021;5(19):3900 - 3912. SCF CD117 JSP191 JSP191 Blocks SCF Binding to CD117 Clinical proof of concept established in two transplant studies with no JSP191 related SAEs to date SCID: • Single agent activity leading to successful donor engraftment and immune reconstitution AML/ MDS: • 17 of 17 patients with successful primary donor engraftment • 12 of 15 with clearance of measurable residual disease • Potential pivotal trial start by Q1 2023
5 JSP191 is an investigative drug and is not approved for any indication New therapeutic approach for disease modification in lower risk MDS patients JSP191 depletes diseased MDS cells in a mouse xenograft model 1 JSP191 targets diseased MDS to potentially restore normal hematopoiesis % depletion of CD34 + CD45RA - CD117 + cells New clinical data: Single dose of JSP191 alone directly depletes stem & progenitor cells 2 AML/MDS subjects receiving JSP191 0.6 mg/kg Time after JSP191 administration  Pang WW, Czechowicz A, Logan AC, et al. Anti - CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenograf ted mice. Blood. 2019;133(19):2069 - 2078.  Jasper Internal Data Proof of concept study in lower risk MDS patients to be initiated in 2022 0% 20% 40% 60% 80% 100%
6 JSP191 is an investigative drug and is not approved for any indication Jasper mRNA technology for transient modification of gene therapy and stem cell grafts Increasing stem cell proliferation, homing and modifying immune profile mRNA transient modification » Increased engraftment of gene therapy & donor stem cell grafts » Reduced risk of graft vs. host disease » Increased safety and utility of cord blood & haploidentical transplant » Single product applicable to multiple diseases CD34+ Hematopoietic Stem Cells • Hematological Malignancies: AML, MDS, ALL, CLL, CML, NHL • Genetic Diseases: Sickle Cell Disease, B Thalassemia, Fanconi Anemia • Autoimmune Diseases: Sclerosis, Aplastic Anemia, Lupus, Multiple Sclerosis • Immunodeficiencies: SCID, Wiskott - Aldrich, LAD, CGD • Infantile Malignant Osteopetrosis (IMO) • Gaucher Disease • Pompe Disease • Fabry Disease • Alzheimer Disease • Frontotemporal Dementia (FTD) • B cells • T Cells • NK cells • Granulocytes • Microglia • Multiple Types • Osteoclasts Multiple Diseases Mature Cells • Red blood cells
7 JSP191 is an investigative drug and is not approved for any indication Indication R&D Partner Research Preclinical Clinical Milestones JSP191 Conditioning Sponsored Studies AML/MDS • Updated Phase Ib data (TCT Meeting on April 26 th ) • Pivotal trial initiation by Q1 2023 SCID • Mid 2023 Phase I/II complete study enrollment Gene Therapy – Sickle Cell • 2H 2022 first patient enrollment Gene Therapy – Gaucher Type 1 • 2H 2022 first patient enrollment Gene Therapy – X - SCID • 2H 2022 first collaboration data Investigator Sponsored Studies Fanconi Anemia • 2022 patient enrollment ongoing Sickle Cell Disease • 2022 patient enrollment Chronic Granulomatous Disease • 2022 patient enrollment GATA2 MDS • 2022 patient enrollment JSP191 Therapeutic Lower Risk MDS (primary treatment) • 2H 2022 clinical study initiation Jasper eHSC Platform Thalassemias, Sickle Cell Disease Autoimmune Diseases Jasper’s Expanding Pipeline Jasper maintains full worldwide rights to develop and commercialize JSP191 and eHSCs in all indications • 2022 – In vivo proof of concept • 2023 – First IND filing
Transforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022